Versions Compared

Key

  • This line was added.
  • This line was removed.
  • Formatting was changed.


Scope 

Project

Scope 

The goals of this project is to obtain broad industry and CRO feedback on the current publicly available OCE/OOD standard safety data request (found at: https://www.fda.gov/media/133252/download) and assist with the development of resources to assist Sponsors with implementation of these data specifications.

There is tremendous variability and inconsistency in the use of the CDISC ADaM data standard in safety datasets for oncology NDA/BLA applications submitted to FDA. This variability leads to inefficiency in review for the FDA and multiple information requests to applicants during the course of the review to resolve inconsistencies in analyses between FDA and applicants. The Oncology Centre of Excellence (OCE)/Office of Oncologic Diseases (OOD) has developed a pilot standard safety data request for datasets submitted with NDA/BLA applications and instructions for conducting select safety analyses to create a common set of data elements with common use of these variables for safety analyses. The Stakeholders include FDA reviewers and analysts, industry, CROs, and software developers.



42021
  • Gained feedback on the OCE/OOD Standard Safety Request v1.3 using Hoylu, an interactive board for collecting comments from participants at the PHUSE CSS 2021. 
  • Consolidated feedback on the use of the dataset specifications at the PHUSE CSS 2021. 

    Status
    colourBlue
    titleCurrent Status
    Q3/

    4 2022

    This project is currently on hold, the team will reach out for volunteers for the kick off of phase 2



    Project LeadsEmail
    Abhilasha Nairabhilasha.nair@fda.hhs.gov
    Chris Pricechris.price@phuse.global 
    Peter Schotland

    peter.schotland@fda.hhs.gov

    Katie Warren

    (PHUSE Project Assistant)

    katie@phuse.global








    DeliverablesTimelines
    Feedback on publicly available OCE/OOD safety data request.
    Q22021
    Q2 2021
    Development of basic resources for sponsors to assist implementation (e.g. CRF design to collect relevant data and linkages for adverse events and dataset preparation for laboratory analyses or other resources requested or found to be needed during the feedback process).
    Q22021Project MembersOrganisationAbhinav SrivastvaExelixisBhupendra MistryRocheBohdan WolosiukPfizer Cathy BezekAstellasCindy MarabottiSanofiDiane WoldCDISCGopi VegesnaAstellasGreg Ball MerckGregory PurnsleyPfizerHitesh ThackerLabcorpHong QiMerckJoy GeMerckKaren YingGSKKen MaahsJanssen Research & DevelopmentKim MusgraveAmgenLihui Deng Bristol Myers SquibbLindsay McLeanPHASTARMarleen NijsJanssen Research & DevelopmentProject MembersOrganisationMatt SmithPfizer

    Maxime Rouch 

    SanofiPaul FrostGEM ProgrammingPavan KumarGSKPeter Bonata BayerBayerSasabindu TripathyTakedaSrinivas KolamuriNovartisSuriaya WalshAstraZenecaSuwen LiRoche

    Tatiana Sotingco

    Janssen Research & DevelopmentTim YoungGSKVenkata Rajesh DatlaGenmabVishnu DabbiruGSKWenyun JiAbbVieWhitney BoeckelGSKWilliam PaloAbbVie
    Q2 2021